CompoAtlas

complexe silhouette

Food supplement declared in France, decision dated 5 November 2026

complexe silhouette (beauty&wild) is a food supplement declared in France. Status: declared in France, may be marketed. 3 rules of use apply to its ingredients (limits and warnings).

Brand
beauty&wild
Food business operator placing the product on the market
Sarl beauty&wild
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules
Directions for use
Prendre 2 gélules par jour avec un grand verre d'eau.
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Pregnant women, Heart problems, Taking anticoagulants, Taking medication, Ulcer (stomach or duodenum)
Objectives stated by the manufacturer (these are not authorised claims)
Weight management / Slimming

Declaration 381396, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Paullinia cupana KunthGraineExtrait sec aqueux224 mg
Camellia sinensis (L.) KuntzeFeuilleExtrait sec aqueux166.67 mg
Cola nitida (Vent.) Schott et Endl.GrainePoudre (de plantes séchées ou broyées)33.33 mg
Foeniculum vulgare Mill.FruitPoudre (de plantes séchées ou broyées)33.33 mg

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Contient de la caféine (environ 66,67 mg/jour). Réservé aux adultes. Déconseillé en cas d’ulcère gastro-duodénal, de troubles cardiaques ou d’hyperthyroïdie ; aux personnes souffrant de troubles de la thyroïde et sous traitement anticoagulant ; en cas d’allergie croisée connue, en particulier à la famille des Apiaceae, au pollen d’armoise ou à l’anéthol. En cas de traitements médicamenteux, demander conseil à un professionnel de santé. L’EGCG ne doit pas être consommé à une quantité égale ou supérieure à 800 mg par jour. Ce produit ne doit pas être consommé si vous prenez le même jour d’autres produits contenant du thé vert. Ne doit pas être consommé par les femmes enceintes ou allaitantes et les enfants de moins de 18 ans. Ne doit pas être consommé à jeun. Ne pas dépasser la dose journalière recommandée. Ce complément alimentaire ne doit pas se substituer à une alimentation variée, équilibrée et à un mode de vie sain. Tenir hors de portée des enfants. Conserver à l’abri de la chaleur et de l’humidité.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Foeniculum vulgare Mill.
    Read the warning, when it applies and the studies cited

    BITTER FENNEL- FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Condition of application: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    Sources cited by Health Canada (1)
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Health Canada monograph dated 29 November 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : beauty&wild

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line